Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

Abstract

The therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib has demonstrated efficacy against advanced gastric cancer and breast cancer, and recent studies have also reported its successful use in non-SCLC; however, its efficacy in SCLC remains unclear. In this study, we used apatinib as salvage therapy for chemotherapy-refractory SCLC. Five male patients with advanced SCLC were administered oral apatinib (250 mg/day) as 2nd- to 4th-line treatment. One patient showed a partial response to apatinib, one showed stable disease, and three patients showed progressive disease. The progression-free survival durations in the patients with stable disease and partial response were 1.5 and 3 months, respectively. Only three patients showed adverse effects, including mild hypertension, vomiting, and hand–foot syndrome, respectively, all of which were manageable. Apatinib might thus be a salvage option in patients with advanced SCLC after chemotherapy.

Keywords

Vascular endothelial growth factor receptor apatinib small cell lung cancer salvage therapy safety survival

Introduction

Small cell lung cancer (SCLC) accounts for 11% of all lung cancers, and is characterized by rapid growth, high aggressiveness, and widespread metastasis.¹ Although SCLC is sensitive to initial chemo-radiotherapy, long-term survivors are rare. The 5-year survival rate of these patients remains low (<7%), and most patients survive for no more than 1 year after diagnosis.² The therapeutic regimen for SCLC has not changed significantly in the past several decades, and studies investigating other chemotherapeutic drugs, molecular targeted drugs, and maintenance chemotherapy have resulted in little improvement.^3,4

Angiogenesis is a crucial hallmark of tumor growth, development, and metastasis. Vascular endothelial growth factor (VEGF) signaling promotes angiogenesis via activating the VEGF receptor (VEGFR), and is thus a critical target of cancer treatment.^5,6 Agents targeting VEGF or VEGFR have demonstrated efficacy in solid tumors, including non-SCLC (NSCLC);^5,6 however, their role in SCLC remains controversial.^7–11 A previous study indicated that the addition of bevacizumab to cisplatin and etoposide in patients with extensive SCLC improved progression-free survival (PFS) and overall survival,¹⁰ but a subsequent report suggested that the addition of bevacizumab to paclitaxel did not improve outcomes in patients with relapsed chemosensitive SCLC.¹¹ Evidence for the use of anti-angiogenesis drugs for SCLC thus remains unclear.

Apatinib is an oral small-molecule inhibitor of VEGFR-2, with proven efficacy in patients with advanced breast and gastric cancers.^12,13 Recent studies have also shown its efficacy in patients with NSCLC.^14–17 We previously reported that low-dose apatinib (250 mg/day) monotherapy resulted in similar PFS to higher-dose apatinib (500–750 mg/day) in patients with NSCLC,^16,17 and was associated with fewer adverse effects in these studies. In a recent case report, apatinib (425 mg/day) combined with pneumonectomy and/or radiotherapy was used in two patients with relapsed SCLC,^18,19 and two other studies also reported on the use of apatinib as maintenance therapy in patients with stable SCLC after induction chemotherapy.^20,21 Another report used higher-dose apatinib (500 mg/day) in patients with extensive SCLC.²² However, there is currently no evidence for the use of low-dose apatinib as monotherapy in patients with advanced SCLC after failure of chemotherapy.

We therefore determined the efficacy and safety of low-dose apatinib (250 mg/day) in patients with advanced chemotherapy-refractory SCLC.

Case Reports

All procedures were carried out according to the guidelines of the Science Council of China and approved by the Research Ethics Committee of Soochow University. Informed consent was obtained from all participants. Three patients had extensive and two had limited SCLC. All patients had pathologically diagnosed SCLC based on transbronchial lung biopsy.

Tumor responses were evaluated every month according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) using chest computed tomography. Objective tumor responses included complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). All adverse effects were also recorded.

The baseline characteristics of the patients are shown in Table 1. All patients received 1st-line platinum-based doublet chemotherapy (platinum and etoposide), with oral apatinib (250 mg/day) as salvage therapy when the disease progressed after 1st- to 3rd-line chemotherapy. Three patients also received lung radiotherapy after 1st-line chemotherapy and one patient received prophylactic craniocerebral radiation.

Table 1.

Characteristics of five patients with small cell lung cancer treated with apatinib.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age (years)	60	64	61	64	71
Sex	Male	Male	Male	Male	Male
Stage	Extensive	Extensive	Limited	Limited	Extensive
Performance score	2	2	2	3	3
Drug treatment
1st-line	Plat+Etop (PD)	Plat+Etop (PR)	Plat+Etop (SD)	Plat+Etop (PR)	Plat+Etop (SD)
PFS1	–	12 months	5 months	9 months	4 months
2nd-line	Irinotecan (PR)	Irinotecan (PD)	Carb+Doc (PD)	Apatinib (PD)	Topotecan (PD)
PFS2	8 months	–	–		–
3rd-line	Docetaxel (PD)	Apatinib (PD)	Irinotecan (PD)		Apatinib (PD)
PFS3	–		–
4th-line	Apatinib (PR)		Apatinib (SD)
PFS4	3 months		1.5 months
Other treatments		Lung radiotherapy and prophylactic craniocerebral radiotherapy	Lung radiotherapy		Lung radiotherapy
Apatinib PFS	3 months	–	1.5 months	–	–
Adverse effects	Hand-foot syndrome	–	Hypertension	Vomiting	–

Plat, platinum; Carb, carboplatin; Etop, etoposide; Doc, docetaxel; SD, stable disease; PD, progressive disease; PR, partial response.

One month after apatinib monotherapy (Table 1 and Figure 1), one patient showed PR (4th-line), one patient showed SD (4th-line), and three patients showed PD (2nd- to 3rd-line). The final PFS durations of the two patients with partial response and stable disease were 1.5 and 3 months, respectively. One patient each developed manageable hypertension and vomiting, respectively, and one patient developed grade 2 hand–foot syndrome.

Figure 1.

Computed tomography scans in five patients before and after apatinib monotherapy. Red arrows indicate tumor mass.

Discussion

There are currently few available drugs for the treatment of patients with SCLC following disease progression after platinum-based chemotherapy. Most patients in the present report received anti-VEGFR2 treatment as 3rd- to 4th-line salvage therapy, except for one patient who received apatinib as 2nd-line treatment because of a poor performance score (3-4). Although anti-VEGF/VEGFR drugs have demonstrated efficacy in patients with advanced NSCLC, there is little evidence for their use in SCLC. The current results support the use of anti-VEGFR treatment as salvage therapy in patients with advanced SCLC. However, further studies are needed to confirm the clinical value of anti-VEGF drugs in SCLC.

We previously showed that low-dose (250 mg/day) apatinib had similar efficacy and fewer adverse reactions to higher-dose apatinib.^16,17 The current results also suggested that a lower dose might be a potential option in patients with advanced SCLC. Two recent reports described the use of apatinib combined with pneumonectomy or/and radiotherapy in two patients with relapsed SCLC,^18,19 while other studies reported on the use of apatinib as maintenance therapy in patients with stable SCLC after induction chemotherapy.^20,21 Low-dose apatinib might thus be a possible therapeutic choice in patients with advanced SCLC. However, further large-scale randomized controlled trials are needed to confirm this. Interestingly, two of the current patients achieved PR or SD after apatinib as 4th-line treatment, and the other patients developed PD after apatinib as 2nd- to 3rd-line treatment. However, this did not mean that apatinib was more effective as 4th-line compared with 2nd-line treatment. Furthermore, the efficacy of low-dose apatinib in other cancers is currently unclear.

This study provides additional information to previous studies. First, apatinib was used as salvage therapy in our study, rather than as maintenance treatment following induction chemotherapy. Furthermore, all patients in our study experienced PD before apatinib administration, rather than being in a stable stage. Second, we used an initial dose of apatinib of 250 mg/day, which was lower than the doses used in most previous studies (500–850 mg/day). We also previously showed that lower-dose apatinib resulted in similar PFS to a higher dose, but with fewer adverse effects.^16,17 This was also indicated in two recent studies of lower-dose apatinib in patients with stable SCLC after induction chemotherapy.^20,21 Another report also indicated that >50% of patients required a dose reduction because of grade 3 or 4 toxicities at an initial dose of 500 mg/day.²² However, the optimal dose of apatinib in SCLC remains unknown. Third, we used apatinib monotherapy in this study rather than combined with pneumonectomy, chemotherapy, or radiotherapy, and there is currently no information on the use of apatinib in combination with chemotherapy or radiotherapy in SCLC.

In conclusion, this report indicated that a low dose of apatinib (250 mg/day) might be an option for salvage treatment in patients with advanced SCLC. However, further studies are needed to determine the optimal dose and to establish the efficacy of apatinib combined with chemotherapy or radiotherapy.

Supplemental Material

IMR887276 Supplemental Material - Supplemental material for Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

Supplemental material, IMR887276 Supplemental Material for Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review by Ying-ying Liu, Tao Chen, Dan Shen, Wei-yun Zhang, Chang-guo Wang, Jun-hong Jiang and Da-xiong Zeng in Journal of International Medical Research

Footnotes

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

This study was supported by Jiangsu Province Special Program of Medical Science (BE2016672), Program of Key Talents of Medical Science in Jiangsu Province (QNRC2016745), Clinical Key Speciality Project of China, Clinical Medicine Center of Suzhou (No. SZZX201502), and Suzhou Key Laboratory for Respiratory Medicine (No. SZS201617).

ORCID iD

Da-xiong Zeng

References

Slotman

van Tinteren

Praag

, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015; 385: 36–42.

Gazdar

Bunn

Minna

JD.

Small-cell lung cancer: what we know, what we need to know and the path forward.

Nat Rev Cancer 2017; 17: 725–737.

Lally

Urbanic

Blackstock

, et al. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 2007; 12: 1096–1104.

Riess

Lara

PM.

Left behind? Drug discovery in extensive stage small cell lung cancer.

Clin Lung Cancer 2014; 15: 93–95.

Sandler

Gray

Perry

, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–2550.

Garon

Ciuleanu

Arrieta

, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384: 665–673.

Meder

Schuldt

Thelen

, et al. Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Res 2018; 78: 4270–4281.

Roviello

Generali

Is there a place for bevacizumab in patients with extensive-stage small cell lung cancer?

Curr Cancer Drug Targets 2016; 16: 209–214.

Pujol

Lavole

Quoix

, et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. Ann Oncol 2015; 26: 908–914.

10.

Horn

Dahlberg

Sandler

, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009; 27: 6006–6011.

11.

Jalal

Bedano

Einhorn

, et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol 2010; 5: 2008–2011.

12.

Zhang

, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer 2014; 135: 1961–1969.

13.

Qin

, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013; 31: 3219–3125.

14.

Zhang

Xiong

, et al. A phase II clinical trial of Apatinib in pretreated advanced non-squamous non-small-cell lung cancer. Clin Lung Cancer 2018; 19: e831–e842.

15.

Zhang

Huang

, et al. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: a retrospective study. Thorac Cancer 2018; 9: 1754–1762.

16.

Zeng

Wang

Lei

, et al. Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. Oncotarget 2017; 8: 66248–66253.

17.

Zeng

Wang

Huang

, et al. Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation. Onco Targets Ther 2017; 10: 4269–4272.

18.

Zhao

Zhang

Gong

, et al. Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: a case report and literature review. Medicine (Baltimore) 2017; 96: e9259.

19.

Pan

Kong

Wang

, et al. A recurrence-free survivor with chemotherapy-refractory small cell lung cancer after pneumonectomy: a case report and review of the literature. Medicine (Baltimore) 2017; 96: e8922.

20.

Yan

Wang

, et al. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study. J Cancer Res Clin Oncol 2019; 145: 235–240.

21.

Luo

Zhang

Yang

, et al. A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer. Invest New Drugs Epub ahead of print. 2019 Aug 9. doi: 10.1007/s10637-019- 00828-x.

22.

Zeng

Jin

, et al. Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study. Cancer Chemother Pharmacol 2019; 83: 1083–1090.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

6.61 MB